Speech-Language Pathologists in Rushville, NY Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Mrs. Melissa Marie Macdowell, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4705 County Road 11, Rushville, NY 14544 Phone: 585-729-8320

Miss Abigail Finley, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 State Route 245, Rushville, NY 14544 Phone: 315-869-6302

Grace Maggio Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5274 Shale Beach Rd, Rushville, NY 14544 Phone: 585-683-8085

Mrs. Lorraine Liput Power, M. S. CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Mothersill Rd, Rushville, NY 14544 Phone: 585-554-6354

Mrs. Cheryl Ann Wagner Macdonald Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4100 Baldwin Rd, Rushville, NY 14544 Phone: 585-554-6441    Fax: 585-554-6176

Kathryn L Burley Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 149 State Route 245, Rushville, NY 14544 Phone: 585-554-3115

News Archive

Rexahn Pharmaceuticals submits Phase II protocol for study of Serdaxin in treatment of PD

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).

Exercising to improve cardiovascular strength may protect from cognitive impairment

Exercising to improve our cardiovascular strength may protect us from cognitive impairment as we age, according to a new study by researchers at the University of Montreal and its affiliated Institut universitaire de gératrie de Montréal Research Centre.

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun.

Poor sense of smell among alcoholics associated with prefrontal cognitive dysfunction

Prior research has shown that chronic alcoholism is associated with numerous olfactory deficits in odor judgment, odor identification, odor sensitivity, and the ability to qualitatively discriminate between odors.

Read more Medical News

› Verified 6 days ago